CN102647971B - 用于包含美洛昔康的组合物的容器 - Google Patents
用于包含美洛昔康的组合物的容器 Download PDFInfo
- Publication number
- CN102647971B CN102647971B CN201080056018.3A CN201080056018A CN102647971B CN 102647971 B CN102647971 B CN 102647971B CN 201080056018 A CN201080056018 A CN 201080056018A CN 102647971 B CN102647971 B CN 102647971B
- Authority
- CN
- China
- Prior art keywords
- plastic containers
- pharmaceutical composition
- sodium benzoate
- volume
- meloxicam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical group OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title claims description 46
- 229960001929 meloxicam Drugs 0.000 title claims description 46
- 239000000203 mixture Substances 0.000 title description 21
- 229920003023 plastic Polymers 0.000 claims abstract description 64
- 239000004033 plastic Substances 0.000 claims abstract description 64
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 60
- 239000004743 Polypropylene Substances 0.000 claims abstract description 46
- 229920001155 polypropylene Polymers 0.000 claims abstract description 46
- -1 polypropylene Polymers 0.000 claims abstract description 42
- 239000005020 polyethylene terephthalate Substances 0.000 claims abstract description 41
- 229920000139 polyethylene terephthalate Polymers 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 229920001577 copolymer Polymers 0.000 claims abstract description 14
- 229920001519 homopolymer Polymers 0.000 claims abstract description 14
- 239000000470 constituent Substances 0.000 claims abstract description 7
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 56
- 235000010234 sodium benzoate Nutrition 0.000 claims description 56
- 239000004299 sodium benzoate Substances 0.000 claims description 56
- 239000000725 suspension Substances 0.000 claims description 20
- 238000004321 preservation Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract description 14
- 239000012611 container material Substances 0.000 abstract description 12
- 239000005711 Benzoic acid Substances 0.000 abstract description 7
- 235000010233 benzoic acid Nutrition 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 7
- 229940124638 COX inhibitor Drugs 0.000 abstract description 4
- 229920001903 high density polyethylene Polymers 0.000 description 14
- 239000004700 high-density polyethylene Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000002421 anti-septic effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 230000021615 conjugation Effects 0.000 description 9
- 229920001684 low density polyethylene Polymers 0.000 description 8
- 239000004702 low-density polyethylene Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005604 random copolymer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- LICPKMHUPOIPDE-WZTVWXICSA-N 4-hydroxy-2-methyl-n-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 LICPKMHUPOIPDE-WZTVWXICSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 239000006171 Britton–Robinson buffer Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- PJJFIVYVZRYVPG-QYGVOOBQSA-K aluminum;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;trihydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PJJFIVYVZRYVPG-QYGVOOBQSA-K 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- DJINZKSHLUSBEQ-UHFFFAOYSA-N boric acid;2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OB(O)O.OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O DJINZKSHLUSBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002650 laminated plastic Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229950006413 sucralox Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1412—Containers with closing means, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2096—Combination of a vial and a syringe for transferring or mixing their contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
- Y10T428/1397—Single layer [continuous layer]
Abstract
本发明涉及一种塑料容器，其含有包含苯甲酸或其衍生物或其药学上可接受的盐和昔康类COX-抑制剂或其药学上可接受的盐的药物组合物，其中所述容器材料选自以下的一种或多种：聚丙烯(PP)的均聚物、聚丙烯(PP)的共聚物、聚对苯二甲酸乙二醇酯(PET)的均聚物和聚对苯二甲酸乙二醇酯(PET)的共聚物和任选地一种或多种非聚合成分。
Description
技术领域
本发明涉及用于含有美洛昔康组合物的储存、分配和保藏的容器。
背景技术
一些药物组合物(例如可注射的组合物)需要在给药前进行灭菌。这些药物组合物必须在无菌条件下生产和储存。WO2008/152122公开了一种用于储存经过灭菌或不经灭菌的化学组合物的多层塑料聚合容器。其公开的瓶具有50ml至500ml的容积。WO2007/087214公开了由聚萘二甲酸乙二醇酯制成的配有闭合装置的塑料容器，其用于储存和保藏苯甲酸钠和头孢地尼的组合物。
关键在于所述容器的材料是药学上可接受的，意思是其不应与药物组合物作用或改变该组合物的量。反过来也一样，该药物组合物不应与所述容器作用或改变所述容器的性质和/或组成。可能发生的任何改变都可能导致化合物在容器材料和/或药物组合物之间迁移。可与溶液混合的来自容器材料的任何化学物质均可成为溶液中的杂质，这些杂质可能通过使该组合物降解影响溶液，或可能以其它方式产生不耐受。在氧气、光和/或温度的作用下，降解作用也可随时间发生。若所述容器和/或溶液经过灭菌(例如辐射)，那么这也可能导致任何材料的降解。由于任何相互作用，所述药物组合物的化学性质(例如活性成分的稳定性)可随时间改变，因此降低了制剂的寿命。另一种必须避免的相互作用是溶液中的任一成分(尤其是苯甲酸钠)被吸收入瓶的材料中。
所述包含美洛昔康的药物组合物是兽医中十分常用的药物，其用于治疗例如疼痛、术后疼痛、炎症、发热、腹泻、跛行、运动器官问题、呼吸疾病、骨关节炎。其不仅可用于不同制剂中，也可用于为了将该药物组合物用于多种动物物种而优化的剂型。
浓度为1.5mg/ml的美洛昔康口服混悬液，用于治疗狗已有十余年的历史。该制剂公开于专利申请WO99/49845中。
此外，已经发现该药物也适于猫的治疗。在狗和猫中，该制剂的可口性(palatability)都是突出的，因此确保了药物治疗的优异顺应性。为猫研发了0.5mg/ml美洛昔康的口服混悬液，这允许了根据动物体重进行精确的给药。
0.5mg/ml美洛昔康的口服混悬液已经批准用于慢性治疗。该混悬液可获自装入15ml该混悬液的25ml高密度聚乙烯(HDPE)瓶中。1.5mg/ml和0.5mg/ml混悬液均可观察到苯甲酸钠含量随时间减少。可证明该防腐剂的减少不仅可解释为化学降解，也可解释为苯甲酸钠被吸入瓶壁中。苯甲酸钠用作防腐剂且为溶液中唯一的物质，其可具有防腐剂的作用，且由于其被吸收，无论在产品的保质期内该制剂是否充分地保藏，其都需要进行测定。可证明在苯甲酸钠含量为标示量的70%即0.15mg/ml，所述制剂仍然满足欧洲药典对于防腐剂效能的所有要求。为延长所述制剂的可能保质期而增加防腐剂的办法是不利的，由于不能完全排除防腐剂可能造成刺激性或变应性反应。这可能造成将给予动物不必要量的防腐剂。
需要更小的瓶用于猫的急性治疗，该瓶含有足以治疗至多5天的所述药物溶液。具有大约3ml的包含0.5mg/ml美洛昔康的口服混悬液的容器将满足这些需要。此外这样的组合物将允许小狗(其具有0.5kg至5kg的体重)、兔和豚鼠等多种其他物种的治疗。因此本发明解决的问题是提供塑料容器，其含有包含苯甲酸或其衍生物或其药学上可接受的盐和昔康类COX-抑制剂或其药学上可接受的盐的药物组合物，其避免苯甲酸或其衍生物在储存中的大量损失。另外，本发明解决的问题是提供含有包含苯甲酸钠和美洛昔康的药物组合物的塑料容器，其避免苯甲酸钠在储存中的大量损失。
发明概述
本发明涉及含有包含苯甲酸或其衍生物或其药学上可接受的盐和昔康类COX-抑制剂或其药学上可接受的盐的药物组合物的塑料容器，其中所述容器材料选自以下的一种或多种：聚丙烯(PP)的均聚物、聚丙烯(PP)的共聚物、聚对苯二甲酸乙二醇酯(PET)的均聚物和聚对苯二甲酸乙二醇酯(PET)的共聚物和任选地非聚合成分。该容器储存和/或保藏包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其中所述容器材料由聚丙烯(PP)或聚对苯二甲酸乙二醇酯(PET)组成，即所述容器材料选自聚丙烯(PP)的均聚物、聚丙烯(PP)的共聚物、聚对苯二甲酸乙二醇酯(PET)的均聚物和聚对苯二甲酸乙二醇酯(PET)的共聚物和任选地非聚合成分。所述容器还包括闭合装置用于储存和保藏药物组合物的闭合装置，其也可连接至分配装置。
用于储存、保藏和/或分配包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物的塑料容器具有3至11ml的容积，其中液体组合物的总体积为2ml至10ml。
瓶内所储存和保藏的药物组合物为含有美洛昔康的组合物，其中美洛昔康浓度为0.2mg/ml至20mg/ml。所述药物组合物还包含苯甲酸钠，其浓度范围为0.8mg/ml至2.0mg/ml。
令人惊讶的是，本发明的容器和包含美洛昔康和苯甲酸钠的药物组合物的组合使该组合物经18个月或至少18个月能够保持基本稳定。
附图说明
图1：PET瓶：随储存时间的苯甲酸钠含量
图2：玻璃瓶：随储存时间的苯甲酸钠含量
图3：PC瓶：随储存时间的苯甲酸钠含量
图4：PP瓶：随储存时间的苯甲酸钠含量
图5：HDPE瓶：随储存时间的苯甲酸钠含量
图6：LDPE瓶：随储存时间的苯甲酸钠含量
图7：储存于25°C/60%相对湿度：PP、HDPE和玻璃瓶的美洛昔康含量(TW=薄壁HDPE瓶)
图8：以整合接合管形式提供的滴器
图9：瓶插入装置：口服/给药注射器
图10：口服/给药注射器
发明详述
本发明涉及含有包含苯甲酸、其衍生物或药学上可接受的盐和昔康类或其药学上可接受的盐的药物组合物的塑料容器，其特征在于所述容器材料为聚丙烯(PP)或聚对苯二甲酸乙二醇酯(PET)。所述塑料容器由含有塑料/聚合物(例如PP或PET)和任选地一种或多种、优选一种或两种、最优选一种非聚合成分的容器材料制成。另外，本发明涉及含有包含苯甲酸、其衍生物或药学上可接受的盐和昔康类COX-抑制剂或其药学上可接受的盐的药物组合物的塑料容器，其中所述容器材料选自以下的一种或多种、优选一种：聚丙烯(PP)的均聚物、聚丙烯(PP)的共聚物、聚对苯二甲酸乙二醇酯(PET)的均聚物和聚对苯二甲酸乙二醇酯(PET)的共聚物和任选地一种或多种非聚合成分。本发明还涉及含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物的塑料容器，其中所述容器材料选自以下的一种或多种、优选一种：聚丙烯(PP)的均聚物、聚丙烯(PP)的共聚物、聚对苯二甲酸乙二醇酯(PET)的均聚物和聚对苯二甲酸乙二醇酯(PET)的共聚物和任选地一种或多种非聚合成分。所述容器配有用于储存和保藏药物组合物的闭合装置。所述容器使得能够稳定保藏所述组合物18个月或至少18个月。在本说明书全文中，术语聚丙烯(PP)是指均聚物、一种或多种共聚物或其组合，尤其是随机共聚物。在本说明书全文中，术语聚对苯二甲酸乙二醇酯(PET)是指均聚物、一种或多种共聚物或其组合，尤其是随机共聚物。
很多种聚合材料通常用于含药物组合物的容器或包装，例如聚氯乙烯(PVC)、聚(乙烯-醋酸乙烯)或任何其他聚烯烃。不同聚合物(例如高密度聚乙烯(HDPE)、低密度聚乙烯(LDPE)、聚碳酸酯(PC)或玻璃)制成的不同类型的容器不适于本发明的用途。只有本发明的材料聚丙烯(PP)和聚对苯二甲酸乙二醇酯(PET)适用并且符合本发明的目的。适于本发明的目的的不同类型的PP例如但不限于：PurellRP270Gwhite(Basell)、RB845MO(Borealis)、PPMR021(TotalAtofina)。已令人惊讶地发现聚丙烯和聚对苯二甲酸乙二醇酯，特别是聚丙烯不会导致防腐剂从溶液中被吸收到瓶壁上，因此可使溶液的稳定性增加。因此本发明涉及含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物的塑料容器，其中所述容器材料为聚丙烯(PP)或聚对苯二甲酸乙二醇酯(PET)，其目的是储存和/或保藏药物组合物。所述容器还包含用于储存和保藏药物组合物的闭合装置。合适的闭合装置为例如两片式显窃启和儿童安全闭合装置。合适的类型为例如LT.9171型盖，由GerresheimerBoleslawiecS.A.，Boleslawiec，Poland供应。
本发明还涉及所述药物组合物的口服分配器，其可连接至所述容器，其允许所述药物组合物精确给药。因此本发明的瓶适于将分配器连接至瓶口。由于需要根据待治疗动物的体重给药精确且灵活的剂量，口服分配器是从所述瓶中给药特定体积的所述制剂的首选。出于该目的，由于所述容器略微可收缩的事实，塑料材料更加合适，使得从瓶中吸出一定体积的液体产生的压力差可忽略不计。该分配设备的材料可包括例如聚乙烯(PE)、低密度聚乙烯(LDPE)或高密度聚乙烯(HDPE)。可连接所述分配器用于给药所述药物组合物，并在使用后拆下。因此所述塑料容器可连接至分配装置。
上述给药系统由塑料接合管(adapter)和给药注射器组成。将所述塑料接合管的底部推入该瓶中。所述接合管具有圆柱形和略微圆锥形的形状。图8给出一个实例。所述接合管还可具有滴器功能，该功能是通过在该塑料部分内的带有孔的板获得的，或是通过在朝向该瓶的漏斗底部具有孔的漏斗状设计而获得的。当将带有所述接合管的具有滴器功能的瓶从水平变为垂直位置时，瓶内的混悬液由于重力作用将向孔的方向流动并滴落。在其他情形下且给药方案不需要这样做时，所述滴器可设计为无孔，因此使得液体恒定地流经圆柱形接合管。这类滴器接合管或尖端(tips)的合适材料为例如LDPE。合适的接合管是市售可得的，例如由Gerresheimer供应。
在不需要滴器功能的情况下，可换用插入(plug-in)装置。图9给出了一个实例。插入装置是一个塑料片，其也通过其底部被推入该瓶中。其上侧是平的并且在其中心具有孔，该孔与给药注射器的尖端相匹配，使得两者间产生紧密的接合，这允许了将具有注射器接入插入装置的瓶翻转并将混悬液吸出至该给药注射器上所需的标记刻线。所述插入装置可由例如LDPE组成。合适的供应商可为HubertDeBacker，Sint-Niklaas，Belgium。图10给出合适的给药注射器的一个实例。其合适的供应商为Baxa或HubertDeBacker。
用于储存、保藏和/或分配包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物的塑料容器中的液体组合物体积为2ml至10ml、2.5ml至8ml、2.5ml至5ml、优选3.5ml至4.5ml、甚至更优选3ml至4.5ml。
用于储存、保藏和/或分配药物组合物的塑料容器中的所述容器容积为3ml至11ml、3ml至10ml、3ml至8ml、3ml至5ml、优选3.5至4.5ml、甚至更优选含有3ml至4ml。
所述容器可例如具有8ml的容积且可含体积为5ml的液体，但其实际上填充液体体积为3.5至4ml，以确保3ml的分配体积。
分配体积可为保证可用性以及因此给药所必须的容积。
本发明的容器可含有包含美洛昔康和苯甲酸钠的溶液或混悬液。所述药物组合物中美洛昔康的优选浓度为0.2mg/ml至20mg/ml，优选0.5mg/ml至15mg/ml，更优选0.5mg/ml、1.5mg/ml或15.0mg/ml。所述药物组合物中苯甲酸钠的优选浓度为0.8mg/ml至2.0mg/ml，优选1.5mg/ml。
所述活性成分可为任何昔康类环氧合酶(COX)抑制剂的非甾体抗炎药，例如美洛昔康、吡罗昔康、氯诺昔康、替诺昔康、屈昔康、伊索昔康，优选美洛昔康。
本发明所用的制剂可含有碱形式的昔康类化合物或其药学上可接受的盐。优选的美洛昔康的盐选自葡甲胺盐、钠盐、钾盐或铵盐，最优选美洛昔康葡甲胺盐。
溶液或混悬液的其他成分包括公知的用于混悬液或溶液的物质，例如助悬剂、防腐剂、矫味剂、pH调节剂和溶剂(例如用于所述制剂的水)。典型混悬液的具体实例列于表1中。
所用助悬剂可为例如有机水胶体形成剂，例如纤维素醚和/或二氧化硅，优选羟乙基纤维素，羟丙基纤维素，羟丙基甲基纤维素和/或二氧化硅或无水胶体二氧化硅，优选无水胶体二氧化硅和/或羟乙基纤维素。
所用防腐剂可为例如苯甲酸或其任何衍生物或盐，优选苯甲酸钠。
所用矫味剂可为例如糖醇，例如甘油、山梨糖醇、甘露醇、木糖醇，或人工甜味剂，例如糖精或其任何盐、环己烷氨基磺酸盐、阿斯巴甜、羟糖铝、索马甜(taumatin)或它们的任何盐、乙酰舒泛钾、其水溶液或其混合物，优选山梨糖醇、甘油糖精或糖精钠和甘油。其他矫味剂可为人工香料，例如人工果味或肉味香料，例如例如蜂蜜、草莓、覆盆子、牛肉或鱼味香料，优选蜂蜜。
所用pH调节剂可为例如磷酸二氢钠二水合物/柠檬酸一水合物缓冲液、甘氨酸/HCl、邻苯二甲酸氢钾/HCl、柠檬酸/磷酸盐、柠檬酸盐-磷酸盐-硼酸盐/HCl或Britton-Robinson缓冲液、其混合物或其与其他生理上可接受的液体(例如甘油或任选地糖醇的水溶液，优选磷酸二氢钠二水合物和柠檬酸一水合物)的混合物。
在另一实施方案中，所述塑料容器由PP或PET制成，其容积为8ml，其包含浓度为0.5mg/ml的美洛昔康和浓度为1.5mg/ml的苯甲酸钠。更具体地，所述塑料容器容积为8ml，其含有体积为3.5ml至4ml的药物组合物，其包含浓度为0.5mg/ml的美洛昔康和浓度为1.5mg/ml的苯甲酸钠。
在另一实施方案中，所述塑料容器由PP或PET制成，其容积为8ml，其含有体积为3.5ml至4ml的药物组合物，其包含浓度为1.5mg/ml的美洛昔康和浓度为0.8mg/ml至2.0mg/ml、优选1.5mg/ml的苯甲酸钠。
在另一实施方案中，所述塑料容器由PP或PET制成，其容积为8ml，其含有体积为3.5ml至4ml的药物组合物，其包含浓度为15.0mg/ml的美洛昔康和浓度为0.8mg/ml至2.0mg/ml、优选1.5mg/ml苯甲酸钠。
装入由不同类型的包装制成的容器的优选的药物组合物，根据VICH指南3所述的条件，已经接受了长期稳定性研究程序。用于储存的条件为25°C/60%相对湿度、30°C/70%相对湿度和40°C/75%相对湿度。
用装入5mlHDPE瓶中的3ml和4ml的混悬液进行0.5mg/ml混悬液的稳定性研究。发现苯甲酸钠令人惊讶地随时间大量减少，即使是在刚刚装入该容器中时，也观察到了由于吸收而造成的防腐剂的显著损失(见图5)。这在此前对任一混悬液(1.5mg/ml或0.5mg/ml)或对不同装入体积都未曾发现。装入10ml(装入25ml瓶中)的1.5mg/ml混悬液保质期为例如至少18个月。对于具有足以治疗猫达数日(多至5日)的体积的商用产品而言，使用HDPE作为容器材料不能达到可接受的保质期。阳性对照(即玻璃瓶)储存0.5mg/ml混悬液，显示苯甲酸钠不随时间减少(见图2)。
表1：
令人惊讶地发现，经18个月或至少18个月的时间中，PP瓶中苯甲酸钠含量的减少显著地低于HDPE或LDPE制成的瓶(见图6)。因此，聚丙烯是用于保存包含美洛昔康和作为防腐剂的苯甲酸钠的小体积口服混悬液的合适材料。PP的适用性进一步通过与PET和PC制成的阴性对照容器进行比较而得以证实，见图1、3和4。
美洛昔康测定随时间变化是非常稳定的，且已证明包装材料的类型对美洛昔康无影响，见图7。
该瓶可为不透明或透明的，优选不透明。
Claims (41)
1.一种塑料容器，其含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其特征在于：
(i)所述药物组合物是混悬液；
(ii)所述容器的材料选自以下的一种或多种：聚丙烯(PP)的均聚物、聚丙烯(PP)的共聚物、聚对苯二甲酸乙二醇酯(PET)的均聚物和聚对苯二甲酸乙二醇酯(PET)的共聚物，以及任选的一或多种非聚合成分；
(iii)所述容器避免苯甲酸钠在储存中的大量损失。
2.权利要求1的塑料容器，其具有用于储存和保藏所述药物组合物的闭合装置。
3.权利要求1的塑料容器，其连接至分配装置。
4.权利要求2的塑料容器，其连接至分配装置。
5.权利要求1的塑料容器，其含有体积为2ml至10ml的药物组合物。
6.权利要求2的塑料容器，其含有体积为2ml至10ml的药物组合物。
7.权利要求3的塑料容器，其含有体积为2ml至10ml的药物组合物。
8.权利要求4的塑料容器，其含有体积为2ml至10ml的药物组合物。
9.权利要求5的塑料容器，其含有体积为2.5ml至8ml的药物组合物。
10.权利要求5的塑料容器，其含有体积为2.5ml至5ml的药物组合物。
11.权利要求5的塑料容器，其含有体积为3.5ml至4.5ml的药物组合物。
12.权利要求5的塑料容器，其含有体积为3ml至4.5ml的药物组合物。
13.权利要求1的塑料容器，其容积为3ml至11ml。
14.权利要求2的塑料容器，其容积为3ml至11ml。
15.权利要求3的塑料容器，其容积为3ml至11ml。
16.权利要求4的塑料容器，其容积为3ml至11ml。
17.权利要求5的塑料容器，其容积为3ml至11ml。
18.权利要求13的塑料容器，其容积为3ml至10ml。
19.权利要求13的塑料容器，其容积为3ml至8ml。
20.权利要求13的塑料容器，其容积为3.5至4.5ml。
21.权利要求13的塑料容器，其容积为3ml至4ml。
22.权利要求1-21中任一项的塑料容器，其含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其中所述美洛昔康是以0.2mg/ml至20mg/ml的浓度存在。
23.权利要求22的塑料容器，其中所述美洛昔康是以0.5mg/ml至15mg/ml的浓度存在。
24.权利要求22的塑料容器，其中所述美洛昔康是以0.5mg/ml的浓度存在。
25.权利要求22的塑料容器，其中所述美洛昔康是以1.5mg/ml的浓度存在。
26.权利要求22的塑料容器，其中所述美洛昔康是以15mg/ml的浓度存在。
27.权利要求1-21中任一项的塑料容器，其含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其中所述苯甲酸钠是以0.8mg/ml至2.0mg/ml的浓度范围存在。
28.权利要求22的塑料容器，其含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其中所述苯甲酸钠是以0.8mg/ml至2.0mg/ml的浓度范围存在。
29.权利要求23的塑料容器，其含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其中所述苯甲酸钠是以0.8mg/ml至2.0mg/ml的浓度范围存在。
30.权利要求24的塑料容器，其含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其中所述苯甲酸钠是以0.8mg/ml至2.0mg/ml的浓度范围存在。
31.权利要求25的塑料容器，其含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其中所述苯甲酸钠是以0.8mg/ml至2.0mg/ml的浓度范围存在。
32.权利要求26的塑料容器，其含有包含苯甲酸钠和美洛昔康或其药学上可接受的盐的药物组合物，其中所述苯甲酸钠是以0.8mg/ml至2.0mg/ml的浓度范围存在。
33.权利要求27的塑料容器，其中所述苯甲酸钠是以1.5mg/ml的浓度存在。
34.权利要求28的塑料容器，其中所述苯甲酸钠是以1.5mg/ml的浓度存在。
35.权利要求29的塑料容器，其中所述苯甲酸钠是以1.5mg/ml的浓度存在。
36.权利要求30的塑料容器，其中所述苯甲酸钠是以1.5mg/ml的浓度存在。
37.权利要求31的塑料容器，其中所述苯甲酸钠是以1.5mg/ml的浓度存在。
38.权利要求32的塑料容器，其中所述苯甲酸钠是以1.5mg/ml的浓度存在。
39.权利要求1-19中任一项的塑料容器，其中：
所述容器具有8ml的容积；和
所述容器包含体积为3.5ml至4ml的药物组合物，所述药物组合物包含浓度为0.5mg/ml的美洛昔康和浓度为1.5mg/ml的苯甲酸钠。
40.权利要求1-19中任一项的塑料容器，其中：
所述容器具有8ml的容积；和
所述容器包含体积为3.5ml至4ml的药物组合物，所述药物组合物包含浓度为1.5mg/ml的美洛昔康和浓度为1.5mg/ml的苯甲酸钠。
41.权利要求1-19中任一项的塑料容器，其中：
所述容器具有8ml的容积；和
所述容器包含体积为3.5ml至4ml的药物组合物，所述药物组合物包含浓度为15.0mg/ml的美洛昔康和浓度为1.5mg/ml的苯甲酸钠。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25070909P | 2009-10-12 | 2009-10-12 | |
| US61/250,709 | 2009-10-12 | ||
| PCT/US2010/052128 WO2011046853A1 (en) | 2009-10-12 | 2010-10-11 | Containers for compositions comprising meloxicam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102647971A CN102647971A (zh) | 2012-08-22 |
| CN102647971B true CN102647971B (zh) | 2016-03-16 |
Family
ID=43432342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080056018.3A Active CN102647971B (zh) | 2009-10-12 | 2010-10-11 | 用于包含美洛昔康的组合物的容器 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9101529B2 (zh) |
| EP (1) | EP2488145B1 (zh) |
| JP (1) | JP5559339B2 (zh) |
| CN (1) | CN102647971B (zh) |
| AU (1) | AU2010307096B2 (zh) |
| CA (1) | CA2777366C (zh) |
| IN (1) | IN2012DN03157A (zh) |
| MX (1) | MX2012004177A (zh) |
| WO (1) | WO2011046853A1 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035107A1 (en) | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| DE10161077A1 (de) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| DE102004021281A1 (de) * | 2004-04-29 | 2005-11-24 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin |
| DE102004030409A1 (de) * | 2004-06-23 | 2006-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Neue Verwendung von Meloxicam in der Veterinärmedizin |
| SG166115A1 (en) * | 2005-09-30 | 2010-11-29 | Boehringer Ingelheim Vetmed | Pharmaceutical preparation containing meloxicam |
| AU2010307096B2 (en) | 2009-10-12 | 2014-07-03 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
| AU2010347598B2 (en) | 2010-03-03 | 2014-11-27 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| JP2018021002A (ja) * | 2016-01-29 | 2018-02-08 | 興和株式会社 | ロキソプロフェンを含有してなる医薬製剤 |
| FR3080368B1 (fr) * | 2018-04-20 | 2021-04-23 | Virbac | Dispositif de protection contre les chocs apte a equiper une bouteille |
| CN110464846B (zh) * | 2018-05-11 | 2023-04-18 | 南京清普生物科技有限公司 | 一种美洛昔康组合物、制剂及其制备方法与应用 |
| CN111846514A (zh) * | 2019-04-30 | 2020-10-30 | 北京蓝丹医药科技有限公司 | 一种氟比洛芬注射液与容器的组合 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682747B1 (en) * | 1998-03-27 | 2004-01-27 | Boehringer Ingelheim Pharma Kg | Process for preparing an oral suspension of a pharmaceutical substance |
| CN1197541C (zh) * | 1998-10-17 | 2005-04-20 | 贝林格尔英格海姆法玛两合公司 | 喷雾器用的二室管状容器 |
| CN1942160A (zh) * | 2004-04-08 | 2007-04-04 | Idd－Eal制造有限公司 | 用于组成液体型制剂的容器 |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2795529A (en) * | 1954-06-17 | 1957-06-11 | American Home Prod | Stabilized hyaluronidase solution containing calcium chloride |
| US3288675A (en) * | 1964-03-20 | 1966-11-29 | Hoffmann La Roche | Parenteral sulfonamide compositions and processes |
| JPS477352Y1 (zh) | 1969-06-13 | 1972-03-17 | ||
| BE789726A (fr) * | 1971-10-06 | 1973-04-05 | Merck & Co Inc | Suppositoires a l'indomethacine |
| US3931212A (en) * | 1973-07-19 | 1976-01-06 | Warner-Lambert Company | Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives |
| US3947576A (en) * | 1973-09-27 | 1976-03-30 | Mortell Company | Synergistic biostatic composition |
| DE2756113A1 (de) | 1977-12-16 | 1979-06-21 | Thomae Gmbh Dr K | Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| FR2437838A1 (fr) | 1978-07-25 | 1980-04-30 | Roecar Holdings Nv | Medicament pour le traitement de l'adenome benin de la prostate |
| JPS56110665A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| DE3217315C2 (de) * | 1982-05-08 | 1986-05-22 | Gödecke AG, 1000 Berlin | Arzneimittelzubereitungen mit einem Gehalt an Oxicam-Derivaten |
| US4543200A (en) * | 1983-09-28 | 1985-09-24 | Sherman Laboratories, Inc. | Contact lens preservative system cleaner and method |
| IT1212778B (it) | 1983-10-07 | 1989-11-30 | Lisapharma Spa | Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene. |
| HU195918B (en) * | 1984-03-14 | 1988-08-29 | Jerome Corbiere | Process for producing pharmaceutical compositions containing non-steroide antiflogistic active components |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| IT1196307B (it) | 1984-10-22 | 1988-11-16 | Chiesi Farma Spa | Formulazioni farmaceutiche acquose di piroxicam monoidrato |
| IT1207994B (it) | 1986-01-03 | 1989-06-01 | Therapicon Srl | Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche. |
| NL8600731A (nl) * | 1986-03-21 | 1987-10-16 | Dmv Campina Bv | Verbeterde gesproeidroogde lactose en werkwijze ter bereiding ervan. |
| US4835187A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
| US5414011A (en) | 1987-09-11 | 1995-05-09 | Syntex (U.S.A.) Inc. | Preservative system for ophthalmic formulations |
| DE3870111D1 (de) | 1987-09-11 | 1992-05-21 | Syntex Inc | Schutzmittel fuer augenzubereitungen. |
| IT1216686B (it) * | 1988-04-01 | 1990-03-08 | Chiesi Farma Spa | Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione. |
| EP0360246B1 (en) | 1988-09-21 | 1994-03-30 | G.D. Searle & Co. | 3-Oxiranyl benzoic acids and derivatives thereof |
| US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| EP0418596A3 (en) * | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
| IL95942A0 (en) | 1989-10-13 | 1991-07-18 | Syntex Inc | Collagen-containing ophthalmic formulation |
| KR920002148A (ko) | 1990-07-03 | 1992-02-28 | 안드레아 엘. 콜비 | 비스테로이드계 소염제에 의해 유발된 위장 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법 |
| US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
| HU205550B (en) * | 1990-11-27 | 1992-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pyroxycam solution of increased stability, free from effects damaging tussues |
| JP3541849B2 (ja) | 1991-04-19 | 2004-07-14 | 久光製薬株式会社 | 消炎鎮痛貼付剤 |
| FR2679135B1 (fr) | 1991-07-18 | 1995-05-19 | Europhta Sa Laboratoire | Nouvelles compositions ophtalmiques a adhesivite amelioree et leurs procedes de preparation. |
| IT1251650B (it) | 1991-10-29 | 1995-05-17 | Boehringer Ingelheim Italia | Composti in incusione di meloxicam con ciclodestrine |
| US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
| JP2860729B2 (ja) | 1992-03-10 | 1999-02-24 | エスエス製薬株式会社 | プラノプロフェン懸濁シロップ剤 |
| DE4217971C1 (de) | 1992-05-30 | 1993-10-21 | Boehringer Ingelheim Vetmed | Verfahren und Wirbelbettapparatur zum Granulieren und/oder Umhüllen |
| US5455271A (en) | 1992-06-18 | 1995-10-03 | The Scripps Research Institute | Tight-binding inhibitors of leukotriene A4 hydrolase |
| US8178516B2 (en) | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
| US5304561A (en) * | 1992-07-24 | 1994-04-19 | Faezeh Sarfarazi | New concept in glaucoma treatment |
| KR0169505B1 (ko) | 1992-09-11 | 1999-01-15 | 오오쓰끼 아끼히꼬 | 약제 포장용 폴리올레핀 포장재, 그의 제조방법 및 약제 포장용 용기 |
| US5380934A (en) * | 1992-10-29 | 1995-01-10 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing alanylgutamine |
| ES2065846B1 (es) | 1993-04-20 | 1995-10-01 | Cusi Lab | Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica. |
| DE4322826A1 (de) | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
| US5676944A (en) | 1993-10-06 | 1997-10-14 | The Regents Of The University Of California | Ocular therapy with homologous macrophages |
| US5474985A (en) | 1993-12-22 | 1995-12-12 | The Regents Of The University Of California | Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors |
| WO1995018604A1 (en) | 1994-01-11 | 1995-07-13 | Ciba-Geigy Ag | Topical treatment of ocular photophobia |
| EP0708646A1 (en) * | 1994-05-06 | 1996-05-01 | Alcon Laboratories, Inc. | Use of vitamin e tocopheryl derivatives in ophthalmic compositions |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5585492A (en) | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
| US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| JP3550782B2 (ja) | 1995-03-14 | 2004-08-04 | 大日本インキ化学工業株式会社 | 乳酸系ポリエステルの発泡性粒子 |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| ATE268176T1 (de) | 1995-07-19 | 2004-06-15 | Merck & Co Inc | Behandlungsverfahren für darmadenome |
| EP0839029A1 (en) | 1995-07-20 | 1998-05-06 | PHARMACIA & UPJOHN COMPANY | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
| DE69636413T2 (de) * | 1995-11-13 | 2007-03-29 | North West University | Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe |
| US5686414A (en) | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
| ES2169351T3 (es) | 1996-02-13 | 2002-07-01 | Searle & Co | Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa. |
| WO1997031631A1 (en) | 1996-02-27 | 1997-09-04 | Rpms Technology Limited | Cox-2 selective inhibitors for managing labour and uterine contractions |
| JP2000513348A (ja) * | 1996-06-20 | 2000-10-10 | ノバルテイス・アクチエンゲゼルシヤフト | 乳腺炎の予防と治療の方法 |
| CA2262595C (en) * | 1996-08-15 | 2005-10-18 | Losan Pharma Gmbh | Easy to swallow oral medicament composition |
| ATA156496A (de) | 1996-09-03 | 1997-10-15 | Nycomed Austria Gmbh | Pharmazeutische zusammensetzung |
| US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
| GB2318511A (en) | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
| US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
| FR2765898B1 (fr) * | 1997-07-10 | 1999-10-01 | Thibierge Et Comar | Papier calque de couleur |
| DE19729879C2 (de) * | 1997-07-11 | 1999-07-08 | Mann Gerhard Chem Pharm Fab | Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin |
| JP2001513563A (ja) * | 1997-08-27 | 2001-09-04 | ヘキサル アーゲー | 溶解性および生物学的利用能の改良されたメロキシカムの医薬組成物 |
| JP4936579B2 (ja) | 1997-09-05 | 2012-05-23 | 第一三共株式会社 | ロキソプロフェン含有医薬製剤 |
| EP1017370B1 (en) * | 1997-09-11 | 2003-10-29 | Nycomed Danmark ApS | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) |
| RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
| SE9703693D0 (sv) * | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
| TW492882B (en) * | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| PT1035835E (pt) | 1997-12-03 | 2003-12-31 | Merck & Co Inc | Formulacoes injectaveis de accao prolongada contendo oleo de ricino hidrogenado |
| US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
| EP0945131A1 (de) | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Perorale Wirkstoff-Suspension |
| EP0945134A1 (de) | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation |
| CA2332271C (en) | 1998-05-15 | 2008-08-05 | Wakamoto Pharmaceutical Co., Ltd. | Selective cyclooxygenase-2 anti-inflammatory eye drops |
| US6319519B2 (en) * | 1998-07-07 | 2001-11-20 | Norton Healthcare Ltd. | Anti-inflammatory pharmaceutical formulations |
| US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| CA2343148C (en) | 1998-09-10 | 2005-11-15 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
| US6180136B1 (en) * | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
| US6156349A (en) * | 1998-12-14 | 2000-12-05 | Steinbach, Pylant And Herman, L.L.C. | Method of treating HIV infection with suppository containing mammalian liver extract |
| US6183779B1 (en) * | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
| US6166012A (en) * | 1999-07-30 | 2000-12-26 | Allergan Sales, Inc. | Antibiotic compositions and method for using same |
| US6552020B1 (en) | 1999-07-30 | 2003-04-22 | Allergan, Inc. | Compositions including antibiotics and methods for using same |
| FR2798289B1 (fr) * | 1999-09-15 | 2004-12-31 | Cll Pharma | Formes galeniques a delitement rapide en bouche et leur procede de preparation |
| WO2001037838A1 (fr) | 1999-11-24 | 2001-05-31 | Wakamoto Pharmaceutical Co., Ltd. | Preparation aqueuse ophtalmique |
| US6685928B2 (en) * | 1999-12-07 | 2004-02-03 | Rutgers, The State University Of New Jersey | Therapeutic compositions and methods |
| KR200182299Y1 (ko) | 1999-12-08 | 2000-05-15 | 장지일 | 플로스 케이스를 포함하는 플로스 홀더 |
| IN191512B (zh) | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
| US6689092B2 (en) * | 2000-03-03 | 2004-02-10 | Boehringer International Gmbh | Needle-less injector of miniature type |
| DE10010123A1 (de) | 2000-03-03 | 2001-09-20 | Boehringer Ingelheim Int | Nadelloser Injektor in Miniaturausführung |
| EP1292381B1 (en) * | 2000-05-03 | 2009-07-15 | D'SILVA, Joe | Process and device for producing liquid dosage formulations |
| AU2001259974A1 (en) * | 2000-05-15 | 2001-11-26 | Merck Frosst Canada & Co | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| DE10024752A1 (de) | 2000-05-16 | 2001-11-29 | Ben Pfeifer | Mittel und Vorrichtung zur Behandlung von Prostata-Erkrankungen |
| WO2001089519A1 (en) * | 2000-05-22 | 2001-11-29 | Nitromed, Inc. | Thromboxane inhibitors, compositions and methods of use related applications |
| DE10030345A1 (de) | 2000-06-20 | 2002-01-10 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen |
| US20020035107A1 (en) * | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| DE10032132A1 (de) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung |
| US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
| JP2004503588A (ja) * | 2000-07-13 | 2004-02-05 | ファルマシア・コーポレーション | 全身性疼痛および頭痛に対する選択的シクロオキシゲナーゼ−２阻害薬および血管調節化合物 |
| ES2223209B1 (es) * | 2001-12-11 | 2005-10-01 | Esteve Quimica, S.A. | Nuevas formas cristalinas del meloxicam y procedimientos para su preparacion e interconversion. |
| GB0022215D0 (en) | 2000-09-11 | 2000-10-25 | Boehringer Ingelheim Pharma | Method for the treatment of thromboembolic disorders in patients with aspirin« resistance |
| DE10300323A1 (de) * | 2003-01-09 | 2004-10-14 | Baxter Healthcare S.A. | Sicherheitsbehälter mit erhöhter Bruch und Splitterfestigkeit sowie kontaminationsfreier Außenfläche für biologisch aktive Substanzen und Verfahren zu deren Herstellung |
| US20040204413A1 (en) * | 2001-01-26 | 2004-10-14 | Joaquina Faour | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant |
| AU2002306868A1 (en) * | 2001-03-28 | 2002-10-15 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
| EP1250921A1 (en) | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
| US20020187187A1 (en) * | 2001-04-21 | 2002-12-12 | Toshimitsu Ohki | Fast disintegrating meloxicam tablet |
| US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
| EP1463806B1 (en) * | 2001-09-28 | 2011-01-05 | Brigham Young University | Novel cyclooxygenase variants and methods of use |
| DE10161077A1 (de) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
| US20040001883A1 (en) * | 2002-03-30 | 2004-01-01 | Boehringer Ingelheim International Gmbh | Meloxicam suppositories |
| EP1348436A1 (en) | 2002-03-30 | 2003-10-01 | Boehringer Ingelheim International GmbH | Meloxicam suppositories |
| US20040024042A1 (en) * | 2002-04-02 | 2004-02-05 | Vanderbilt University | COX2 inhibition in the prevention and treatment of autosomal dominant polycystic kidney disease |
| DE10223013A1 (de) | 2002-05-22 | 2003-12-04 | Boehringer Ingelheim Int | Verwendung von Meloxicam für die Linderung von Organverletzungen während Organoperation oder -transplantation |
| WO2004004776A1 (en) | 2002-07-09 | 2004-01-15 | B.M.R.A. Corporation B.V. | Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| US20040037869A1 (en) * | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
| AU2003263599A1 (en) * | 2002-09-17 | 2004-04-08 | Nippon Boehringer Ingelheim Co., Ltd. | Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer. |
| WO2004026116A2 (en) | 2002-09-19 | 2004-04-01 | The Regents Of The University Of California | Use of etodoclac to treat hyperplasia |
| US20040171611A1 (en) * | 2002-09-30 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline acetic acid solvate of meloxicam |
| US8992980B2 (en) * | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| DE10250081A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Vetmedica Gmbh | Wasserlösliche Meloxicam Granulate |
| CA2413705A1 (en) * | 2002-12-06 | 2004-06-06 | Raul Altman | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
| US20050197332A1 (en) * | 2002-12-10 | 2005-09-08 | Boehringer Ingelheim International | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
| US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
| WO2004078113A2 (en) * | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
| US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| DE10315702A1 (de) | 2003-04-07 | 2004-10-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis |
| US20040198826A1 (en) * | 2003-04-07 | 2004-10-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination for treating benign prostatic hyperplasia or for treating abacterial prostatitis |
| JP4018022B2 (ja) | 2003-04-10 | 2007-12-05 | 株式会社ホシモト | 開閉用ハンドル装置 |
| US20050159419A1 (en) | 2003-05-14 | 2005-07-21 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage |
| PE20050386A1 (es) | 2003-05-29 | 2005-06-23 | Schering Plough Ltd | Composiciones farmaceuticas de florfenicol |
| WO2005004915A2 (en) | 2003-07-09 | 2005-01-20 | Boehringer Ingelheim International Gmbh | Compositions comprising meloxicam |
| US20050038018A1 (en) * | 2003-07-09 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Meloxicam compositions |
| US20050147664A1 (en) * | 2003-11-13 | 2005-07-07 | Elan Pharma International Ltd. | Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| DE102004021281A1 (de) | 2004-04-29 | 2005-11-24 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin |
| DE102004025324A1 (de) | 2004-05-19 | 2005-12-08 | Boehringer Ingelheim Vetmedica Gmbh | Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung |
| DE102004030409A1 (de) * | 2004-06-23 | 2006-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Neue Verwendung von Meloxicam in der Veterinärmedizin |
| AU2005313365A1 (en) * | 2004-12-06 | 2006-06-15 | Janssen Pharmaceutica N.V. | Oral suspension comprising meloxicam |
| CA2602374A1 (en) | 2005-03-23 | 2006-09-28 | Boehringer Ingelheim International Gmbh | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor |
| JP4929448B2 (ja) | 2005-07-29 | 2012-05-09 | 財団法人ヒューマンサイエンス振興財団 | 断層撮影装置 |
| MXPA05010505A (es) * | 2005-09-29 | 2007-03-28 | Leopoldo Espinosa Abdala | Forma farmaceutica que contiene metocarbamol, meloxicam y betametasona. |
| SG166115A1 (en) | 2005-09-30 | 2010-11-29 | Boehringer Ingelheim Vetmed | Pharmaceutical preparation containing meloxicam |
| ATE459686T1 (de) * | 2005-12-20 | 2010-03-15 | Basell Poliolefine Srl | Polypropylenzusammensetzungen für gestreckte artikel |
| US20070187405A1 (en) | 2006-01-23 | 2007-08-16 | Pujara Chetan P | Container for compositions containing cefdinir |
| US20070249727A1 (en) * | 2006-04-21 | 2007-10-25 | The Proctor & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
| JP4321624B2 (ja) | 2007-05-21 | 2009-08-26 | 株式会社デンソー | 半導体素子駆動回路 |
| FR2917381B1 (fr) * | 2007-06-15 | 2009-10-16 | Ceva Sante Animale Sa | Conditionnement plastique multicouche pour la conservation d'une composition pharmaceutique |
| CA2702261A1 (en) | 2007-10-12 | 2009-04-16 | Map Pharmaceuticals, Inc. | Inhalation drug delivery |
| GB0724707D0 (en) | 2007-12-19 | 2008-01-30 | Burke Michael H | A process for the preparation of an orally administered unit dose tablet |
| AU2010307096B2 (en) | 2009-10-12 | 2014-07-03 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
| US20110218191A1 (en) | 2010-03-03 | 2011-09-08 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long term-treatment of kidney disorders in cats |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
-
2010
- 2010-10-11 AU AU2010307096A patent/AU2010307096B2/en active Active
- 2010-10-11 WO PCT/US2010/052128 patent/WO2011046853A1/en active Application Filing
- 2010-10-11 CN CN201080056018.3A patent/CN102647971B/zh active Active
- 2010-10-11 US US12/901,649 patent/US9101529B2/en active Active
- 2010-10-11 EP EP10771837.1A patent/EP2488145B1/en active Active
- 2010-10-11 IN IN3157DEN2012 patent/IN2012DN03157A/en unknown
- 2010-10-11 MX MX2012004177A patent/MX2012004177A/es not_active Application Discontinuation
- 2010-10-11 CA CA2777366A patent/CA2777366C/en active Active
- 2010-10-11 JP JP2012534260A patent/JP5559339B2/ja active Active
-
2013
- 2013-03-13 US US13/799,901 patent/US9186296B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682747B1 (en) * | 1998-03-27 | 2004-01-27 | Boehringer Ingelheim Pharma Kg | Process for preparing an oral suspension of a pharmaceutical substance |
| CN1197541C (zh) * | 1998-10-17 | 2005-04-20 | 贝林格尔英格海姆法玛两合公司 | 喷雾器用的二室管状容器 |
| CN1942160A (zh) * | 2004-04-08 | 2007-04-04 | Idd－Eal制造有限公司 | 用于组成液体型制剂的容器 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102647971A (zh) | 2012-08-22 |
| US20130161228A1 (en) | 2013-06-27 |
| US9186296B2 (en) | 2015-11-17 |
| EP2488145B1 (en) | 2024-04-24 |
| AU2010307096B2 (en) | 2014-07-03 |
| JP5559339B2 (ja) | 2014-07-23 |
| US9101529B2 (en) | 2015-08-11 |
| US20110083985A1 (en) | 2011-04-14 |
| WO2011046853A1 (en) | 2011-04-21 |
| AU2010307096A1 (en) | 2012-04-19 |
| EP2488145A1 (en) | 2012-08-22 |
| CA2777366C (en) | 2023-11-14 |
| CA2777366A1 (en) | 2011-04-21 |
| MX2012004177A (es) | 2012-05-08 |
| IN2012DN03157A (zh) | 2015-09-18 |
| JP2013507440A (ja) | 2013-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102647971B (zh) | 用于包含美洛昔康的组合物的容器 | |
| CN107049929B (zh) | 甲状腺激素t3和/或t4的单次剂量药物制剂 | |
| BR112012001899B1 (pt) | soluções compreendendo polietileno glicol e eletrólitos, seu método de preparação, e recipiente e kit que as compreendem | |
| JP6745798B2 (ja) | パラセタモール及びイブプロフェンを含む水性配合物 | |
| JP7262528B2 (ja) | ジルチアゼムの非経口投薬形態 | |
| CN113577019A (zh) | 即可灌注的吉西他滨溶液 | |
| US9364393B1 (en) | Packaging system for liquid medications | |
| US20130288968A1 (en) | Leuprolide injection | |
| CN106038538A (zh) | 一种右美托咪定的预混合制剂 | |
| US11766438B2 (en) | Pharmaceutical compositions of tofacitinib for oral administration | |
| JP2015533619A (ja) | 医療用カートリッジに緩衝剤及び他の物質を追加する方法及び装置 | |
| CN117881392A (zh) | 室温下稳定的水性罗库溴铵组合物 | |
| AU2008332806C1 (en) | Pharmaceutical compositon for cleansing of the bowel | |
| JP2009143902A (ja) | エダラボンを含有する安定な水溶性製剤 | |
| JP2004217645A (ja) | 注射剤 | |
| JP6081102B2 (ja) | 安定なグラニセトロン含有水性製剤 | |
| US20230301986A1 (en) | Ready-to-administer hydromorphone formulations | |
| JP2008029681A (ja) | 薬剤充填容器 | |
| JP2001261579A (ja) | 脂溶性ビタミン可溶化液 | |
| Allen Jr | Didanosine 10 mg/mL Oral Suspension | |
| US20230210865A1 (en) | Midazolam premix formulations and uses thereof | |
| JP2001327575A (ja) | 液剤用容器 | |
| JP2006025953A (ja) | ホリナート類水溶液充填プレフィルドシリンジ包装体 | |
| JP2007222270A (ja) | 薬剤包装物 | |
| JP2017077484A (ja) | 安定なグラニセトロン含有水性製剤の包装体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |